Visual‐somatosensory integration as a novel behavioral marker of amyloid pathology
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.14561 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Jeannette R Mahoney und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Division of Cognitive and Sensorimotor Aging, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York,…. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Amyloid beta-Peptides, Visual Perception. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, Resnick Gerontology Center of the Albert Einstein College of Medicine.
Abstract (Originalsprache)
INTRODUCTION The ability to integrate information across sensory modalities is a vital aspect of everyday functioning and is linked to cognition. Increasing evidence suggests that Alzheimer's disease (AD) pathology manifests in sensory association areas before appearing in higher‐order cognitive areas. We examined the role of visual‐somatosensory integration (VSI) as a novel behavioral marker of AD‐associated amyloid pathology. METHODS This cross‐sectional study included 243 adults (77 ± 6.5 years; 52% female) who completed the VSI test and AD biomarker assays. The magnitude of VSI was the independent variable and amyloid‐beta probability scores (APS; PrecivityAD TM ) were the dependent variable . Cognitive status (normal, mild cognitive impairment, or AD) was assigned during case conferences. RESULTS Linear regression revealed an inverse association between the magnitude of VSI and APS ( β = −0.16; p ≤ 0.01). As cognitive impairment increased from normal to dementia, the magnitude of VSI decreased ( p < 0.05). DISCUSSION Findings provide support for VSI impairment as a new behavioral marker of AD‐associated amyloid pathology. Highlights Here we provide support for the magnitude of VSI as a novel behavioral marker of AD‐associated amyloid pathology given its significant association with an established, accurate, and reliable biomarker of AD pathology. Adults with normal cognition maintained the highest magnitude of VSI and brain amyloid negative scores. As cognitive impairment increased, the mean magnitude of VSI significantly decreased while amyloid probability scores (APS) increased. In fact, individuals with dementia revealed the lowest magnitude of VSI and the highest APS. Our research continues to emphasize the importance of successful multisensory integration in aging, where the establishment of future novel multisensory‐based interventions aimed at preventing disability and optimizing independence could prove valuable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Division of Cognitive and Sensorimotor Aging, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
ORCID-Profile: Jeannette R Mahoney
Förderung
- NIA NIH HHS
- NIH HHS
- Resnick Gerontology Center of the Albert Einstein College of Medicine
- National Institutes of Health
- National Institute on Aging
Zitieren
APA
Mahoney, J. R., Ayers, E., & Verghese, J. (2025). Visual‐somatosensory integration as a novel behavioral marker of amyloid pathology. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14561
Vancouver
Mahoney JR, Ayers E, Verghese J. Visual‐somatosensory integration as a novel behavioral marker of amyloid pathology. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14561
BibTeX
@article{Mahoney2025,
author = {Mahoney, Jeannette R and Ayers, Emmeline and Verghese, Joe},
title = {Visual‐somatosensory integration as a novel behavioral marker of amyloid pathology},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.14561}
}
EUVIMED